HK1078768A1 - Compositions for the treatment of gastrointestinaldisorders - Google Patents
Compositions for the treatment of gastrointestinaldisordersInfo
- Publication number
- HK1078768A1 HK1078768A1 HK05110618A HK05110618A HK1078768A1 HK 1078768 A1 HK1078768 A1 HK 1078768A1 HK 05110618 A HK05110618 A HK 05110618A HK 05110618 A HK05110618 A HK 05110618A HK 1078768 A1 HK1078768 A1 HK 1078768A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- disorders
- constipation
- conditions
- dyspepsia
- functional
- Prior art date
Links
- 208000018522 Gastrointestinal disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010010774 Constipation Diseases 0.000 abstract 4
- 201000006549 dyspepsia Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 abstract 2
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 abstract 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 201000005078 Colonic Pseudo-Obstruction Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 abstract 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 abstract 1
- 206010021518 Impaired gastric emptying Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 abstract 1
- 208000001288 gastroparesis Diseases 0.000 abstract 1
- 208000024798 heartburn Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44309803P | 2003-01-28 | 2003-01-28 | |
| US47128803P | 2003-05-15 | 2003-05-15 | |
| US51946003P | 2003-11-12 | 2003-11-12 | |
| PCT/US2004/002390 WO2004069165A2 (en) | 2003-01-28 | 2004-01-28 | Methods and compositions for the treatment of gastrointestinal disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1078768A1 true HK1078768A1 (en) | 2006-03-24 |
Family
ID=32854294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK05110618A HK1078768A1 (en) | 2003-01-28 | 2005-11-23 | Compositions for the treatment of gastrointestinaldisorders |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20040266989A1 (el) |
| EP (3) | EP1594517B1 (el) |
| JP (3) | JP4584911B2 (el) |
| KR (2) | KR101227627B1 (el) |
| CN (2) | CN100589839C (el) |
| AT (2) | ATE365174T1 (el) |
| AU (2) | AU2004210161B2 (el) |
| BE (1) | BE2013C032I2 (el) |
| BR (2) | BR122018074353B8 (el) |
| CA (1) | CA2514507C (el) |
| CY (5) | CY1110905T1 (el) |
| DE (2) | DE602004028678D1 (el) |
| DK (3) | DK1911763T3 (el) |
| ES (3) | ES2350123T3 (el) |
| FR (2) | FR13C0030I1 (el) |
| HK (1) | HK1078768A1 (el) |
| HU (1) | HUS1300022I1 (el) |
| IL (2) | IL169863A (el) |
| LT (1) | LTC1594517I2 (el) |
| LU (2) | LU92200I2 (el) |
| MX (1) | MXPA05008097A (el) |
| NL (1) | NL300593I2 (el) |
| NO (2) | NO334112B1 (el) |
| NZ (2) | NZ541595A (el) |
| PT (3) | PT1911763E (el) |
| RU (2) | RU2543350C2 (el) |
| SG (2) | SG168407A1 (el) |
| SI (3) | SI1911763T1 (el) |
| WO (1) | WO2004069165A2 (el) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2622468T3 (es) | 2001-03-29 | 2017-07-06 | Synergy Pharmaceuticals, Inc. | Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis |
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| ES2350123T3 (es) | 2003-01-28 | 2011-01-18 | Ironwood Pharmaceuticals, Inc. | Composiciones para el tratamiento de trastornos gastrointestinales. |
| US20060281682A1 (en) * | 2003-01-28 | 2006-12-14 | Currie Mark G | Methods and compositions for the treatment of gastrointestinal disorders |
| US7494979B2 (en) * | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
| US20070010450A1 (en) * | 2003-06-13 | 2007-01-11 | Microbia, Inc., A Massachusetts Corporation | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2005115412A2 (en) * | 2004-05-25 | 2005-12-08 | University Of Georgia Research Foundation, Inc. | Compositions and methods for modulating an immune response |
| EP1813271A4 (en) * | 2004-10-26 | 2008-05-21 | Ajinomoto Kk | PREVENTIVE / THERAPEUTIC AGENT FOR VISCERAL PAIN |
| CA2619650A1 (en) * | 2005-08-19 | 2007-02-22 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2007041278A2 (en) | 2005-09-29 | 2007-04-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Composition and methods for stimulating gastrointestinal motility |
| US20090305993A1 (en) * | 2006-02-24 | 2009-12-10 | Ironwood Pharmaceuticals, Inc. | Methods and composition for the treatment of gastrointestinal disorders |
| EP2129683A4 (en) * | 2007-02-26 | 2011-01-05 | Ironwood Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS |
| MX2009011898A (es) * | 2007-05-04 | 2009-11-18 | Ironwood Pharmaceuticals Inc | Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| ES2393885T7 (es) | 2007-06-04 | 2014-01-30 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| JP2011523662A (ja) | 2008-06-04 | 2011-08-18 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| US20110306125A1 (en) * | 2008-06-30 | 2011-12-15 | Ironwood Pharmaceuticals, Inc. | Protein Expression Methods |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| HUE049023T2 (hu) * | 2008-08-15 | 2020-08-28 | Ironwood Pharmaceuticals Inc | Linaklotidot tartalmazó, szájon át történõ beadásra szolgáló készítmények |
| CA2743172A1 (en) | 2008-11-19 | 2010-05-27 | Forest Laboratories Holdings Limited | Crystalline form of linaclotide |
| US20100221329A1 (en) | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| CN102482326A (zh) * | 2009-04-10 | 2012-05-30 | 科登制药科罗拉多公司 | 分离治疗用肽的方法 |
| WO2011017502A2 (en) * | 2009-08-06 | 2011-02-10 | Ironwood Pharmaceuticals, Inc. | Linaclotide-containing formulations for oral administration |
| WO2011020054A1 (en) | 2009-08-13 | 2011-02-17 | Ironwood Pharmaceuticals Inc. | Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists |
| MX2012005368A (es) | 2009-11-09 | 2012-06-13 | Ironwood Pharmaceuticals Inc | Tratamientos para transtornos gastrointestinales. |
| JP5984675B2 (ja) * | 2009-12-07 | 2016-09-06 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | 胃腸障害の療法 |
| UA108636C2 (xx) | 2010-02-17 | 2015-05-25 | Пептид | |
| WO2011145062A1 (en) | 2010-05-21 | 2011-11-24 | Link Research & Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
| WO2011156453A2 (en) | 2010-06-09 | 2011-12-15 | Combimab, Inc. | Therapeutic peptides |
| RS59978B1 (sr) | 2010-08-11 | 2020-03-31 | Ironwood Pharmaceuticals Inc | Stabilne formulacije linaklotida |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| EP2621509A4 (en) | 2010-09-15 | 2016-08-03 | Synergy Pharmaceuticals Inc | PREPARATIONS OF GUANYLATE CYCLASE-C AGONISTS AND METHODS OF USE |
| US9303066B2 (en) | 2011-05-11 | 2016-04-05 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| WO2012155101A1 (en) | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| WO2012170804A1 (en) | 2011-06-08 | 2012-12-13 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| US9527887B2 (en) | 2011-06-08 | 2016-12-27 | Ironwood Pharmaceutical, Inc. | Treatments for gastrointestinal disorders |
| MD480Z5 (ro) * | 2011-07-07 | 2012-09-30 | Эльвира АНДОН | Metodă de tratament al colitei ulceroase nespecifice acute |
| DK2776055T3 (en) | 2011-08-17 | 2017-03-06 | Ironwood Pharmaceuticals Inc | TREATMENTS FOR GASTROINTESTINAL DISORDERS |
| EA022546B1 (ru) * | 2011-09-28 | 2016-01-29 | Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук | Способ торможения роста карциномы эрлиха у лабораторного животного |
| WO2014088623A1 (en) * | 2012-07-12 | 2014-06-12 | Forest Laboratories Holdings Limited | Linaclotide compositions |
| RU2528641C2 (ru) * | 2012-08-22 | 2014-09-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации | Способ лечения больных с синдромом диспепсии в сочетании с избыточной массой тела |
| CN102875655B (zh) * | 2012-09-29 | 2014-12-17 | 深圳翰宇药业股份有限公司 | 一种合成利那洛肽的方法 |
| US20150361139A1 (en) | 2013-01-30 | 2015-12-17 | Sandoz Ag | Crystalline form of linaclotide |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| JP6694385B2 (ja) | 2013-08-09 | 2020-05-13 | アーデリクス，インコーポレーテッド | リン酸塩輸送阻害のための化合物及び方法 |
| LT3288578T (lt) * | 2015-05-01 | 2023-04-25 | Ironwood Pharmaceuticals, Inc. | Kompozicijos, skirtos gaubtinės žarnos valymui ir virškinimo trakto sutrikimų gydymui |
| WO2017160938A1 (en) * | 2016-03-15 | 2017-09-21 | The Regents Of The University Of California | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH α8β1 INTEGRIN |
| CN107929718A (zh) * | 2017-10-19 | 2018-04-20 | 南京星银药业集团有限公司 | Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法 |
| CN117599320A (zh) * | 2018-10-23 | 2024-02-27 | 艾比科生物医学公司 | 输送装置 |
| CN109467606A (zh) * | 2018-11-15 | 2019-03-15 | 大连理工大学 | 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用 |
| JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス， インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
| RU2712761C1 (ru) * | 2019-07-02 | 2020-01-31 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких |
| CN111265653B (zh) * | 2020-02-09 | 2023-05-09 | 华中科技大学同济医学院附属协和医院 | 心房利钠肽在制备炎症性肠病治疗药物中的应用 |
| US20230035733A1 (en) * | 2020-03-26 | 2023-02-02 | Dusa Pharmaceuticals, Inc. | Management of dermal neurofibromatosis lesions |
| WO2023144292A1 (en) | 2022-01-28 | 2023-08-03 | Fresenius Kabi Ipsum S.R.L. | Process for the preparation of linaclotide |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US73628A (en) * | 1868-01-21 | mitchell | ||
| US258687A (en) * | 1882-05-30 | Grain-binder | ||
| US152868A (en) * | 1874-07-07 | Improvement in type-setting machines | ||
| US266989A (en) * | 1882-11-07 | Automatic fire | ||
| US232013A (en) * | 1880-09-07 | Henry h | ||
| US121961A (en) * | 1871-12-19 | Improvement in devices for supporting pipe-cores | ||
| US32684A (en) * | 1861-07-02 | Stump-extkactob | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US6342373B1 (en) * | 1983-11-21 | 2002-01-29 | Ucp Gen-Pharma Ag | Process for preparing recombinant eglin, protease inhibitor |
| IT1217123B (it) | 1987-02-05 | 1990-03-14 | Rotta Research Lab | Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| CH679207A5 (el) | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
| HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| FR2674849B1 (fr) | 1991-04-02 | 1994-12-23 | Logeais Labor Jacques | Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique. |
| CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| US5140102A (en) | 1991-09-23 | 1992-08-18 | Monsanto Company | Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase |
| DE69233125T2 (de) * | 1991-12-02 | 2004-04-22 | Millennium Pharmaceuticals, Inc., South San Francisco | Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor |
| US5824645A (en) | 1991-12-30 | 1998-10-20 | Neurex Corporation | Method of treating inflammation |
| DE69225499T2 (de) | 1991-12-30 | 1999-02-04 | Neurex Corp | Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5969097A (en) * | 1992-06-23 | 1999-10-19 | G. D. Searle & Co. | Human guanylin |
| SG47043A1 (en) | 1993-01-06 | 1998-03-20 | Kinerton Ltd | Ionic molecular conjugates of biodegradeble polyesters and bioactive polypeptides |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5395490A (en) * | 1993-05-14 | 1995-03-07 | Intertec, Ltd. | Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies |
| JP4194113B2 (ja) * | 1993-10-26 | 2008-12-10 | トーマス・ジェファーソン・ユニバーシティ | 結腸直腸癌細胞に特異的に結合する組成物およびその使用方法 |
| US5489670A (en) * | 1993-10-29 | 1996-02-06 | G. D. Searle & Co. | Human uroguanylin |
| US5610145A (en) | 1994-04-15 | 1997-03-11 | Warner-Lambert Company | Tachykinin antagonists |
| US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| DK1336409T3 (da) | 1995-06-27 | 2007-08-13 | Eisai R&D Man Co Ltd | Sammensætninger af formuleringer til fremstilling af analgesimidler og til hæmning af fremadskridende neuropatiske smertelidelser |
| US6054429A (en) | 1996-03-08 | 2000-04-25 | Elan Pharmaceuticals, Inc. | Epidural method of producing analgesia |
| US5795864A (en) | 1995-06-27 | 1998-08-18 | Neurex Corporation | Stable omega conopetide formulations |
| IL124522A0 (en) | 1995-11-24 | 1998-12-06 | Smithkline Beecham Spa | Quinoline derivatives |
| GB9524104D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
| CZ299398A3 (cs) | 1996-04-23 | 1999-01-13 | Kinerton Limited | Kyselé polylaktické polymery |
| US6589750B2 (en) | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
| AU6823098A (en) | 1997-02-28 | 1998-09-18 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists |
| US5893985A (en) | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
| NZ329807A (en) | 1997-04-23 | 2000-07-28 | Pfizer | NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome |
| JP2001516765A (ja) | 1997-09-12 | 2001-10-02 | ヴォルフ ゲオルグ フォースマン | 真性糖尿病及び肥満の治療のための組成物 |
| US20010006972A1 (en) | 1998-04-21 | 2001-07-05 | Stephen A. Williams | Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome |
| IT1304152B1 (it) | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| NZ516477A (en) | 1999-06-23 | 2004-02-27 | Pasteur Institut | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| JP4303438B2 (ja) | 1999-08-18 | 2009-07-29 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | ペプチドの持続放出製剤 |
| SE9903291D0 (sv) | 1999-09-15 | 1999-09-15 | Astra Ab | New process |
| AU7700400A (en) | 1999-10-06 | 2001-05-10 | Pharmacia Corporation | Uroguanylin as an intestinal cancer inhibiting agent |
| CZ299726B6 (cs) | 1999-11-01 | 2008-11-05 | Lécivo pro lécení zácpy a syndromu dráždivého tracníku | |
| AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
| WO2001064212A1 (en) | 2000-03-01 | 2001-09-07 | University College London | Modulators of the endocannabinoid uptake and of the vallinoid receptors |
| EP1216707B1 (en) | 2000-12-22 | 2005-02-09 | Institut Pasteur | Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide |
| EP1365753A2 (en) | 2001-02-02 | 2003-12-03 | Pharmacia Corporation | Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| ES2622468T3 (es) | 2001-03-29 | 2017-07-06 | Synergy Pharmaceuticals, Inc. | Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis |
| WO2002079235A2 (en) | 2001-03-30 | 2002-10-10 | University Of Copenhagen | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease |
| MY134211A (en) | 2001-05-18 | 2007-11-30 | Smithkline Beecham Corp | Novel use |
| EP1392729A2 (de) | 2001-06-05 | 2004-03-03 | Yalcin Cetin | Verwendung eines peptids, welches guanylat cyclase c aktiviert, für die behandlung von atemwegserkrankungen über die luftwege, arzneimittel, inhalationsvorrichtung und diagnoseverfahren |
| FR2830451B1 (fr) | 2001-10-09 | 2004-04-30 | Inst Nat Sante Rech Med | Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur |
| EP1321142A1 (en) | 2001-12-21 | 2003-06-25 | Novartis AG | Solid pharmaceutical composition for oral administration of Tegaserod |
| US20040121961A1 (en) | 2002-02-04 | 2004-06-24 | Jaime Masferrer | Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| US20030232013A1 (en) | 2002-02-22 | 2003-12-18 | Gary Sieckman | Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides |
| EP1531846A4 (en) | 2002-02-27 | 2006-04-19 | Us Gov Health & Human Serv | CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES |
| US20030203055A1 (en) | 2002-03-15 | 2003-10-30 | Cypress Bioscience, Inc. | Methods of treating visceral pain syndromes |
| KR101108014B1 (ko) | 2002-05-17 | 2012-01-25 | 티오가 파마슈티칼스, 인코포레이티드 | 선택성 아편제 수용체 조절인자로서 효과적인 화합물의 용도 |
| US20060281682A1 (en) | 2003-01-28 | 2006-12-14 | Currie Mark G | Methods and compositions for the treatment of gastrointestinal disorders |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7304036B2 (en) * | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| ES2350123T3 (es) * | 2003-01-28 | 2011-01-18 | Ironwood Pharmaceuticals, Inc. | Composiciones para el tratamiento de trastornos gastrointestinales. |
| WO2004071436A2 (en) | 2003-02-10 | 2004-08-26 | Thomas Jefferson University | The use of gcc ligands |
| CA2619650A1 (en) * | 2005-08-19 | 2007-02-22 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
-
2004
- 2004-01-28 ES ES07011869T patent/ES2350123T3/es not_active Expired - Lifetime
- 2004-01-28 PT PT07011869T patent/PT1911763E/pt unknown
- 2004-01-28 AU AU2004210161A patent/AU2004210161B2/en active Active
- 2004-01-28 PT PT04706011T patent/PT1594517E/pt unknown
- 2004-01-28 AT AT04706011T patent/ATE365174T1/de active
- 2004-01-28 CA CA2514507A patent/CA2514507C/en not_active Expired - Lifetime
- 2004-01-28 DK DK07011869.0T patent/DK1911763T3/da active
- 2004-01-28 NZ NZ541595A patent/NZ541595A/en not_active IP Right Cessation
- 2004-01-28 CN CN200480008533A patent/CN100589839C/zh not_active Expired - Lifetime
- 2004-01-28 AT AT07011869T patent/ATE477268T1/de active
- 2004-01-28 DE DE602004028678T patent/DE602004028678D1/de not_active Expired - Lifetime
- 2004-01-28 SG SG200705302-8A patent/SG168407A1/en unknown
- 2004-01-28 SI SI200431521T patent/SI1911763T1/sl unknown
- 2004-01-28 RU RU2008147983/15A patent/RU2543350C2/ru active
- 2004-01-28 DE DE602004007105T patent/DE602004007105T2/de not_active Expired - Lifetime
- 2004-01-28 CN CN2009102662250A patent/CN101787073B/zh not_active Expired - Lifetime
- 2004-01-28 DK DK10170038.3T patent/DK2246360T3/da active
- 2004-01-28 SG SG2012003802A patent/SG192300A1/en unknown
- 2004-01-28 SI SI200430401T patent/SI1594517T1/sl unknown
- 2004-01-28 JP JP2006503109A patent/JP4584911B2/ja not_active Expired - Lifetime
- 2004-01-28 NZ NZ570134A patent/NZ570134A/en not_active IP Right Cessation
- 2004-01-28 EP EP04706011A patent/EP1594517B1/en not_active Expired - Lifetime
- 2004-01-28 RU RU2005127058/15A patent/RU2353383C2/ru active
- 2004-01-28 WO PCT/US2004/002390 patent/WO2004069165A2/en active Application Filing
- 2004-01-28 EP EP10170038A patent/EP2246360B1/en not_active Expired - Lifetime
- 2004-01-28 EP EP07011869A patent/EP1911763B1/en not_active Expired - Lifetime
- 2004-01-28 DK DK04706011T patent/DK1594517T3/da active
- 2004-01-28 BR BR122018074353A patent/BR122018074353B8/pt active IP Right Grant
- 2004-01-28 BR BRPI0407071A patent/BRPI0407071B8/pt active IP Right Grant
- 2004-01-28 SI SI200431918T patent/SI2246360T1/sl unknown
- 2004-01-28 ES ES10170038T patent/ES2387848T3/es not_active Expired - Lifetime
- 2004-01-28 PT PT10170038T patent/PT2246360E/pt unknown
- 2004-01-28 KR KR1020117019764A patent/KR101227627B1/ko active IP Right Grant
- 2004-01-28 US US10/766,735 patent/US20040266989A1/en not_active Abandoned
- 2004-01-28 ES ES04706011T patent/ES2285417T3/es not_active Expired - Lifetime
- 2004-01-28 KR KR1020057013966A patent/KR101227626B1/ko active IP Right Grant
- 2004-01-28 MX MXPA05008097A patent/MXPA05008097A/es active IP Right Grant
-
2005
- 2005-07-25 IL IL169863A patent/IL169863A/en active IP Right Grant
- 2005-08-18 NO NO20053864A patent/NO334112B1/no not_active IP Right Cessation
- 2005-11-23 HK HK05110618A patent/HK1078768A1/xx not_active IP Right Cessation
-
2007
- 2007-08-09 CY CY20071101072T patent/CY1110905T1/el unknown
- 2007-10-31 US US11/930,696 patent/US7704947B2/en not_active Expired - Lifetime
-
2009
- 2009-11-10 AU AU2009235993A patent/AU2009235993B2/en active Active
-
2010
- 2010-04-05 US US12/754,138 patent/US8080526B2/en not_active Expired - Lifetime
- 2010-06-22 JP JP2010141519A patent/JP5563384B2/ja not_active Expired - Lifetime
- 2010-11-04 CY CY20101101000T patent/CY1111058T1/el unknown
-
2012
- 2012-08-09 IL IL221380A patent/IL221380A0/en active IP Right Grant
- 2012-09-19 CY CY20121100859T patent/CY1113217T1/el unknown
-
2013
- 2013-02-28 JP JP2013038602A patent/JP5748791B2/ja not_active Expired - Lifetime
- 2013-04-05 NO NO20130460A patent/NO336768B1/no not_active IP Right Cessation
- 2013-05-22 HU HUS1300022 patent/HUS1300022I1/hu unknown
- 2013-05-22 LU LU92200C patent/LU92200I2/fr unknown
- 2013-05-22 NL NL300593C patent/NL300593I2/nl unknown
- 2013-05-22 LT LTPA2013013C patent/LTC1594517I2/lt unknown
- 2013-05-22 LU LU92201C patent/LU92201I2/fr unknown
- 2013-05-23 FR FR13C0030C patent/FR13C0030I1/fr active Active
- 2013-05-23 FR FR13C0029C patent/FR13C0029I2/fr active Active
- 2013-05-24 BE BE2013C032C patent/BE2013C032I2/nl unknown
- 2013-05-24 CY CY2013021C patent/CY2013021I1/el unknown
- 2013-05-24 CY CY2013022C patent/CY2013022I1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1300022I1 (hu) | Készítmények gasztrointesztinális rendellenességek kezelésére | |
| SG153824A1 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2005016244A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2007022531A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2006086653A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2007101158A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2008002971A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2005074575A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| EA201290799A1 (ru) | Лечение желудочно-кишечных расстройств | |
| WO2007062168A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| IL171356A (en) | Anti-interferon receptor antibody for treatment of inflammatory bowel disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHRG | Changes in the register |
Free format text: [72] NORMAN, THEA ADDITION OF PRIORITY CLAIM: |
|
| PE | Patent expired |
Effective date: 20240127 |